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Abstract  
 Acetylcholine is an important neurotransmitter in the mammalian brain.  This 
transmitter binds to muscarinic acetylcholine receptors (mAChR) to regulate activity of a 
variety of intracellular signaling molecules.  Fyn and Src are two members of the Src family 
kinase (SFK).  They are highly expressed in many brain regions, including the striatum, an 
area in the forebrain critical for cognitive, reward, mood, and movement.  Since the striatum 
is also among brain regions showing a high level of mAChR expression, it is intriguing to 
investigate whether mAChRs regulate Fyn and Src.  In this study, this topic was investigated 
by testing the effect of pharmacological blockade of mAChRs on phosphorylation of Fyn and 
Src at a specific tyrosine site, tyrosine 416 (Y416), a phosphorylation event leading to 
activation of Fyn and Src.  A widely used mAChR antagonist scopolamine was used to block 
mAChRs and changes in phosphorylation of SFK Y416 were examined in the two 
subdivisions of the striatum, i.e., the caudate putamen (CPu) and nucleus accumbens (NAc), 
using Western blot with a phospho- and site-specific anti-Y416 antibody.  We found that a 
single intraperitoneal injection of scopolamine at an effective dose (5 mg/kg) induced a 
significant increase in Y416 phosphorylation in the CPu.  A similar increase in Y416 
phosphorylation was also seen in the NAc following scopolamine administration.  The 
scopolamine-stimulated Y416 phosphorylation was time-dependent.  No significant change 
occurred to the amount of total Fyn and Src proteins in the two regions.  These results 
indicate that mAChRs exert an inhibitory effect on basal phosphorylation of Fyn and Src in 
striatal neurons under normal conditions. 
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1. Introduction  
 Acetylcholine (ACh) is a key neurotransmitter in the striatum, an area which contains 
more choline acetyltransferase (ChAT), ACh, muscarinic acetylcholine receptors (mAChR), 
and acetylcholinesterase than other tissues 9, 13. The striatum which consists of the caudate 
putamen (CPu) and nucleus accumbens (NAc) is involved in the regulation of sensorimotor, 
cognitive, and limbic functions and is linked to various neuropsychiatric and 
neurodegenerative disorders 3. ACh within the striatum is mainly provided by aspiny 
cholinergic interneurons (ChI) that are the largest locally found but are few in numbers in the 
striatum (only 1-2% of the total striatal cell population) 2, 3, 7. Despite low numbers, ChIs 
exert their significant influence over GABAergic projection neurons also called medium 
spiny neurons (MSNs) by extremely dense and branched axonal arbors 3, 13.  
 Cholinergic receptors are divided into two subclasses: inotropic nicotinic cholinergic 
receptors (nAChRs) and G protein-coupled mAChRs 3. mAChRs have been classified into 
five subtypes (M1-M5) with all transcripts expressed in the striatum 3, 4. These subtypes are 
further categorized into two groups on the basis of their distinct pharmacological properties 
upon activation: the Gq-coupled M1-like receptors (M1, M3, and M5) that enhance internal 
Ca2+ release through stimulation of phospholipases, and the Gi/o-coupled M2-like receptors 
(M2 and M4) that inhibit adenylyl cyclase and thereby reduce cAMP formation 3, 12.  
 There is a highly heterogeneous distribution of M1-M5 receptors throughout the 
striatum, which contributes to the distinguishing features of the cholinergic system in the 
region 3. The highest level of M1 receptor binding is seen in the striosomes of the caudate 
nucleus and the lowest expression is in the insula major of Calleja, although M1 mAChR 
mRNA and binding sites are heterogeneously expressed throughout each striatal region 3, 9. 
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M2 expression is moderate in the dorsal CPu and the NAc core, while the NAc shell and the 
insula major of Calleja express denser M2 receptor binding sites 3. M3 receptor mRNA and 
binding site pattern of expression significantly differs from that of M1 and M2 receptors. 
Specifically, they are mainly enriched in the mid-ventral and ventral regions of the caudate 
and striatum 3. M4 are the most prevalent striatal mAChRs 3, 9. M5 mAChRs have shown 
minimal staining in the striatum; however, lack of sensitive M5 receptor antibodies may 
explain these findings 3.  
 Src family kinases (SFK) are non-receptor tyrosine kinases and the largest known 
family of this type of kinases 5, 8. They play key roles in cell differentiation, motility, 
proliferation, and survival 11. Their 52-62 kDa protein structure is composed of six distinct 
functional regions: (1) the Src homology (SH) 4 domain, (2) the unique region, (3) the SH3 
domain, (4) the SH2 domain, (5) the catalytic domain, and (6) a short negative regulatory tail 
1. The SH2 and SH3 domains play a central role in regulating SFK catalytic activity by 
stabilizing the inactive conformation 11. The inactive conformation is displaced by two main 
modulatory actions: (1) dephosphorylation of pY527 in the negative regulatory tail, which 
normally promotes intramolecular interactions with the SH2 domain keeping the kinase in a 
closed inactive conformation, and (2) phosphorylation of Y416 in the catalytic domain, 
which induces a conformational change that allows the kinase to assume an active 
conformation 8, 11. Importantly, these modular domains endow SFKs with the ability to be 
regulated by and to communicate with a diverse group of proteins 11. As such, SFKs play a 
vital role in regulating the cellular responsivity to extracellular stimulation. In regard to Src 
and Fyn specifically, they are shown to be ubiquitously expressed in the cell body; however, 
Src has particularly higher levels of expression (5-200 times more) in platelets, neurons, and 
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osteoclasts 5, 6, 11. Src is implicated in a variety of cellular processes such as proliferation, 
differentiation, and migration, while Fyn is also diversely implicated in such processes as 
cellular adhesion, T-cell signaling, and brain functions 5, 6. Interestingly, Fyn knockout mice 
have shown abnormal hippocampal development, defects in learning and memory, and 
decreased myelination, which further enforces its potential for being integral in striatal ChI 
function 5. 
 SFK activity has previously shown to be regulated by many different G protein-
coupled receptors (GPCR), including Gi/o and Gq protein-coupled receptors 11. Evidence for 
this is apparent as multiple GPCRs increased SFK catalytic activity (two- to threefold) 11. 
One particular intracellular signaling molecule downstream to GPCRs is cAMP which has 
been shown to modulate SFKs activity 1, 10. Schmitt and Stork have demonstrated a link 
between cAMP and SFKs by showing that protein kinase A (PKA) phosphorylated Src at 
serine 17, which in turn caused autophosphorylation of Src at Y416 and led to activation of 
Src 10. In addition, Yeo et al. preformed a similar experiment to determine whether PKA 
regulates Fyn activity and found that PKA phosphorylated Fyn at serine 21, which is a step 
deemed to be essential for Fyn kinase activity 14.  
 How GPCRs induce SFK activation has not been elucidated in many tissues. This 
indicates an intriguing question to whether or not there is a connection between mAChRs in 
the striatum and modulation of SFK phosphorylation. Here we investigated the role of 
mAChRs in regulating SFK phosphorylation at the Y416 residue in the rat striatum in vivo. 
By understanding this potential link, further exploration can be made to better understand the 
role of striatal ChIs in the regulation of striatal neurons.  
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2. Materials and methods 
2.1. Animals  
 Adult male Wistar rats (210-300 g; Charles River, NewYork, NY) were housed in 
pairs in a controlled environment at a constant temperature of 23°C and humidity of 50 ± 
10% with food and water available ad libitum. The animal room was on a 12-h/12-h 
light/dark cycle. Rats were allowed 6-7 days of habituation to the facility. All animal use and 
procedures were in strict accordance with the US National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional Animal Care 
and Use Committee. 
 
2.2. Drug administration and protein extraction 
 Rats received an intraperitoneal (i.p.) injection of systemically active agents in a 
volume of 1 ml/kg. Doses of agents were calculated as the salt. An effective dose (5 mg/kg, 
i.p.) of the mAChR antagonist scopolamine for a systemic injection was determined by 
literature and our previous studies. After drug injection, rats were anesthetized and 
decapitated. Rat brains were removed and coronal slices were cut. The CPu and NAc regions 
were dissected from slices. Brain tissue was homogenized in a radioimmunoprecipitation 
assay (RIPA) buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, and 1 µg/ml leupeptin (Cell Signaling Technology, 
Danvers, MA).  Homogenates were centrifuged at 800 g for 10 min (4°C) and supernatants 
were collected.  Protein concentrations were determined. Samples were stored at -80°C until 
use. 
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2.3. Western Blot  
 As described previously (Van Dolah et al., 2011; Jin et al. 2013), proteins were 
separated on SDS NuPAGE Novex 4-12% gels (Invitrogen, Carlsbad, CA) and transferred to 
polyvinylidene fluoride membranes (Millipore, Bedford, MA). Membranes after blocking 
were incubated in a solution containing a primary rabbit antibody overnight at 4°C. This was 
followed by incubation in a horseradish peroxidase-linked secondary antibody. Immunoblots 
were developed with an enhanced chemiluminescence reagent (GE Healthcare Life Sciences, 
Piscataway, NJ). Optical density of immunoblots was measured using NIH gel analysis 
software.  
 
2.4. Antibodies and pharmacological agents  
 Primary antibodies used in this study include rabbit antibodies against phospho-SFKs 
at Y416 (Cell Signaling Technology, Beverly, MA) which detects a phosphorylated tyrosine 
at position 416 on SFKs, Src (Cell Signaling), Fyn (Santa Cruz Biotechnology, Santa Cruz, 
CA), or actin (Cell Signaling). The pharmacological agent used is (-)-scopolamine 
hydrobromide, which was purchased from Sigma-Aldrich. Scopolamine was dissolved in a 
physiological saline solution and was freshly prepared on the day of the experiment.   
 
2.5. Statistics  
 The results are presented as means ±SEM. These results were statistically analyzed 
using a one way analysis of variance followed by a Bonferroni (Dunn) comparison of groups 
using least squares-adjusted means. Probability levels of <0.05 were considered statistically 
significant.  
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Fig. 1. (A) Representative immunoblots showing effects of scopolamine on pY416 phosphorylation, 
Fyn total, Src total, and Actin (control) in the caudate putamen. (B-D) Quantification of effects of 
scopolamine on SFKs phosphorylation at pY416 (B), Fyn total protein (C), and Src total protein (D) 
at sacrifice intervals of 0, 7.5, 15, 30 min. Data are presented as mean ±SEM (n = 4 per group).  
Fig. 2. (A) Representative immunoblots showing effects of scopolamine on pY416 phosphorylation, 
Fyn total, Src total, and Actin (control) in the nucleus accumbens. (B-D) Quantification of effects of 
scopolamine on SFKs phosphorylation at pY416 (B), Fyn total protein (C), and Src total protein (D) 
at sacrifice intervals of 0, 7.5, 15, 30 min. Data are presented as mean ±SEM (n = 4 per group).  
A B C D 
A B C D 
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3. Results  
 We first investigated the role of mAChR antagonism in changing the phosphorylation 
of SFKs at a specific tyrosine site, Y416. To this end, we randomly divided rats into four 
different groups (n = 4 per group). This size of group was determined by a power analysis 
and our previous experiments of this kind. We subjected three groups of rats to a single dose 
of the mAChR antagonist scopolamine (5 mg/kg, i.p.). These rats were sacrificed at different 
time points (7.5, 15, and 30 min after drug injection) to detect changes in SFK 
phosphorylation at Y416 in the striatum using immunoblots. One group of rats received a 
saline injection and were sacrificed immediately (0 min after injection) to serve as a control. 
We found that a single injection of scopolamine consistently increased levels of Y416 
phosphorylation in the CPu at a later time point (30 min), while scopolamine did not alter 
Y416 phosphorylation at two early time points (7.5 and 15 min) (Fig. 1A and 1B). Similar 
results were seen in the NAc of scopolamine-treated rats compared to saline-treated rats (Fig. 
2A and 2B). These data reveal a time-dependent response of Y416 phosphorylation to 
scopolamine.  Blockade of mAChRs with scopolamine is able to induce a relatively delayed 
increase in Y416 phosphorylation in both the CPu and NAc.  
 We next analyzed the same samples from four groups of rats to determine if 
scopolamine alters protein expression of the two prototypic members of SFKs, Fyn and Src, 
in the CPu and NAc. At all time points surveyed, Fyn and Src protein levels remained 
unchanged in the CPu following scopolamine administration (Fig. 1C and 1D). Similarly in 
the NAc, we observed the insensitivity of Fyn and Src protein expression in response to 
scopolamine as the two proteins showed a minimal change in scopolamine-treated rats 
relative to saline-treated rats (Fig. 2C and 2D).  These data demonstrate that mAChR 
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blockade has no significant impact on total Fyn and Src protein expression in the CPu and 
NAc.  
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Fig. 3. Diagram depicting the signaling pathways involved in SFKs phosphorylation in the 
striatum in response to a single scopolamine injection (see discussion for details). (1.) 
Scopalomine blocks mAChR. (2.) mAChR can’t activate Gαi which would inhibit 
adenylyl cyclase. (3.) Adenylyl cyclase stays active & makes cAMP. (4.) cAMP activates 
PKA. (5.) PKA phosphorylates SFK. (6.) Activated SFK causes downstream effects 
through molecular mechanisms that are currently poorly understood. mAChR, muscarinic  
acetylcholine receptor; GPCR, G-protein coupled receptor (αi); GDP, guanosine 
diphosphate; GTP, guanosine triphosphate; cAMP, cyclic adenosine monophosphate; 
ATP, adenosine triphosphate; ADP, adenosine diphosphate; PKA, protein kinase A; SFK, 
Src Family Kinase; P, phosphate.  
 
Created by Hunter Faris 
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4. Discussion  
 In this study, the possible role of mAChRs in the regulation of SFKs was investigated 
in the adult rat striatum in vivo. Important findings from this study include that 1) 
pharmacological blockade of mAChRs with a widely-used antagonist scopolamine increased 
phosphorylation of SFKs in the two subdivisions of the striatum, i.e., the CPu and NAc, and 
2) the mAChR antagonist did not change expression of total Src and Fyn proteins within the 
striatum. These results for the first time provide evidence supporting a significant role of 
mAChRs in the regulation of SFKs.  Since the mAChR antagonist elevated SFK 
phosphorylation, mAChRs are believed to exert an inhibitory influence on SFK activity in 
striatal neurons under normal conditions.  
While our data demonstrate that mAChRs regulate SFKs, how mAChRs regulate 
SFKs is unclear.  Early studies have shown that PKA is among regulators that modulate SFK 
activity (see Introduction).  In details, activation of PKA leads to an increase in Y416 
phosphorylation of SFKs 10, 14. Among five mAChR subtypes, M2 and M4 receptors are 
known to be coupled to Gi/o proteins. As a result, activation of M2 and M4 receptors inhibits 
adenylyl cyclase, leading to reduction of cAMP formation and reduction of PKA activity. 
Thus, it is likely that scopolamine may mainly target M2 and/or M4 receptors. By blocking 
these receptors, scopolamine removes the M2/M4-mediated inhibition of PKA activity. This 
results in a higher level of PKA activity, which thereby enhances SFK phosphorylation (Fig. 
3) 1, 10, 14.  
Between M2 and M4 receptors, the M4 receptor is more intriguing because the M4 
receptor is the most prevalent striatal mAChRs seen in all subregions of the striatum and is 
thus likely to exert the most profound effect on striatal signaling and activity 3, 9. However, 
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one limitation of this work is the non-subtype selective nature of scopolamine. Using this 
antagonist is not able to reveal information on the subtype of mAChRs responsible for the 
regulation of SFKs. Future studies will use an M4 receptor selective antagonist, if available, 
to define the selective role of M4 receptors in the regulation of SFKs.  
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